Melanóma: ki dolgozik rajta

Intézményenként egy kártya. Célpontra vagy országra szűkítheted a listát.

• Minden célpont
• PD-1 54
• BRAF 18
• PD-L1 21
• MEK 7
• TP53 0
• CTLA-4 10
• MAPK 2
• NRAS 8
• STING 0
• STAT3 0
• PRAME 3
• AKT 0
• PI3K 0
• BAP1 2
• VEGF 4
• mTOR 0
• ERK 0
• LAG-3 2
• RAS 2
• CTNNB1 0
• CD40 0
• CDKN2A 3
• TNF 0
• YAP 0
• PTEN 1
• JAK 0
• KIT 3
• KRAS 1
• JNK 0
• PPAR 0
• TIGIT 0
• ALK 0
• B7-H3 3
• BCL-2 0
• EZH2 0
• HIF-1 0
• IL-15 1
• NF1 2
• NLRP3 0
• NRF2 0
• AMPK 0
• HSP90 0
• CD47 0
• MYC 0
• PKM2 0
• AXL 1
• COX-2 0
• EGFR 0
• GPX4 0
• MET 1
• HDAC 1
• IDH 1
• IL-17 1
• MMP-9 0
• CDK4/6 0
• CXCR4 0
• FGFR 0
• HER2 3
• IGF1R 0
• PSMA 3

59+ intézményből 24, a friss publikációk és a nyitott vizsgálatok szerint rendezve. Ez nem minőségi rangsor.

Funded research projects that name this disease in their title, terms or summary and have not ended yet: who is funded, where, how much and until when. Organisations only; the funder's page has the details.

• NIH NIAID · F32

  Investigating the mechanisms of KLRG1-mediated immune suppression in regulatory T cells

  Brown University· Providence, Egyesült Államok· 79 780 USD awarded in fiscal year 2026· until 2029. okt.

• ALLCDC NCCDPHP · R43

  Parents and Schools for Sun Safety (PASS): A Family-Based Skin Cancer Prevention Program for Schools

  Klein Buendel, Inc.· Lakewood, Egyesült Államok· 311 239 USD awarded in fiscal year 2026· until 2027. szept.

• NIH NCI · R21

  Optimizing TIL Harvest Site and Patient Selection with CD8-PET Imaging

  University of Tx Md Anderson Can Ctr· Houston, Egyesült Államok· 421 685 USD awarded in fiscal year 2026· until 2028. aug.

• NIH NIAMS · R00

  Investigating the Role of Cancer-Associated Fibroblasts in Immunodetection of Mycosis Fungoides

  Beckman Research Institute/City of Hope· Duarte, Egyesült Államok· 249 000 USD awarded in fiscal year 2026· until 2029. aug.

• NIH NIA · R43

  RadBot: Next-Generation Drug Discovery for Environmental Stress Resistance Using Longevity Biology

  Ora Biomedical, Inc.· Tukwila, Egyesült Államok· 299 783 USD awarded in fiscal year 2026· until 2027. szept.

• European Commission (Horizon Europe) · HORIZON-TMA-MSCA-PF-EF

  Predicting immunotherapy response in melanoma and non-small cell lung cancer patients using an extracellular vesicle-derived miRNA signature and a non-invasive CRISPR-based detection assay. (IT-PREDICT)

  Centre Georges-Francois Leclerc Association· Dijon, Franciaország· EU contribution 242 261 EUR· until 2029. márc.

• European Commission (Horizon Europe) · HORIZON-ERC-POC

  Lipopolysaccharide Lipid A Profiling to Guide Microbiome-Supported Immunotherapy in Melanoma (LPS-Pro)

  Universita Degli Studi di Napoli Federico Ii· Napoli, Olaszország· EU contribution 150 000 EUR· until 2028. jún.

• European Commission (Horizon Europe) · HORIZON-ERC-POC

  Validation of artificial intelligence-based minibinders and inhibitors of Midkine in immune resistant tumours (MDK_MINIBINDERS)

  Fundacion Sector Publico Estatal Centro Nacional Investigaciones Oncologicas Carlos Iii· Madrid, Spanyolország· EU contribution 150 000 EUR· until 2028. ápr.

  The disease is named only in the funder's project summary, not in the title.

• European Commission (Horizon Europe) · HORIZON-RIA

  Decoding Early-Life UVA and Skincare Additive Interactions Driving Melanoma Risk and Progression in Young Adults (PhotoMel)

  Medizinische Universitaet Wien· Wien, Ausztria· EU contribution 5 709 196 EUR· until 2030. aug.· 5 countries

• European Commission (Horizon Europe) · HORIZON-TMA-MSCA-DN

  SPAtial single-CEll omics research training for MELanoma precision medicine (SPACE-MEL)

  Katholieke Universiteit Leuven· Leuven, Belgium· EU contribution 4 565 428 EUR· until 2030. aug.· 9 countries

10 of 1011 running projects, newest first. Listed amounts together: 571,0 M USD + 83,4 M EUR.

Sources: NIH RePORTER (U.S. National Institutes of Health, public domain) and CORDIS (European Commission, CC BY 4.0). Changes: filtered by disease, organisations matched to ROR.

Leállított, visszavont és felfüggesztett vizsgálatok, a szponzor által a regiszterben megadott okkal, szó szerint idézve.

• Felfüggesztve

  The Effect of Diet and Exercise on ImmuNotherapy and the Microbiome (EDEN)

  NCT04866810· National Cancer Institute (NCI)· Frissítve: 2026. okt. 19.

  “On hold pending planned interim analysis.”A regiszter szövege, változtatás nélkül. Forrás

• Leállították

  A Study of Botensilimab (AGEN1181) for the Treatment of Advanced Melanoma

  NCT05529316· Agenus Inc.· Frissítve: 2026. okt. 19.

  “Sponsor decision”A regiszter szövege, változtatás nélkül. Forrás

• Leállították

  Study of CTX-471 as a Monotherapy or in Combination With Pembrolizumab in Patients Post PD-1/PD-L1 Inhibitors in Metastatic or Locally Advanced Malignancies

  NCT03881488· Compass Therapeutics· Frissítve: 2026. okt. 9.

  “The combination therapy arm of the study with pembrolizumab did not yield an efficacy signal, so enrollment into the combination therapy arm was terminated. The monotherapy arm of the study was fully enrolled and completed.”A regiszter szövege, változtatás nélkül. Forrás

• Felfüggesztve

  Novel RNA-lipid Particle (RNA-LP) Vaccine for Anti-PD-1 Antibody Therapy Sensitization

  NCT05264974· University of Florida· Frissítve: 2026. szept. 17.

  “seeking additional funding”A regiszter szövege, változtatás nélkül. Forrás

• Leállították

  Rigosertib Plus Pembrolizumab in Treating Patients With Unresectable/Metastatic Melanoma Refractory to PD-1 Inhibitors

  NCT05764395· Vanderbilt-Ingram Cancer Center· Frissítve: 2026. szept. 16.

  “Drug unavailable”A regiszter szövege, változtatás nélkül. Forrás

• Leállították

  High Dose IL-2 in Combination With Anti-PD-1

  NCT03991130· Gregory Daniels· Frissítve: 2026. aug. 6.

  “Lack of funding”A regiszter szövege, változtatás nélkül. Forrás

• Leállították

  Identifying the Predictive Factors of Response to PD-1 or PD-L1 Antagonists

  NCT03412058· UNICANCER· Frissítve: 2026. aug. 3.

  “The study was terminated prematurely due to insufficient patient recruitment”A regiszter szövege, változtatás nélkül. Forrás

• Leállították

  Defining the Role of the Skin Microbiome in Immune-related Adverse Events

  NCT04734704· University Hospital, Bordeaux· Frissítve: 2026. jún. 23.

  “target number of patients not reached and disabling team changes”A regiszter szövege, változtatás nélkül. Forrás

• Leállították

  Pembrolizumab and Lenvatinib in Patients With Brain Metastases From Melanoma or Renal Cell Carcinoma

  NCT04955743· Yale University· Frissítve: 2026. jún. 4.

  “Lack of activity in the drugs”A regiszter szövege, változtatás nélkül. Forrás

• Leállították

  Study of PF-07265807 in Participants With Metastatic Solid Tumors.

  NCT04458259· Pfizer· Frissítve: 2026. jún. 4.

  “Pfizer has made an internal business decision to not continue further development of PF-07265807. This decision was not due to major safety concerns or requests from any regulatory authorities.”A regiszter szövege, változtatás nélkül. Forrás

Vizsgálatok, amelyek regiszteradata szerint az egyéni résztvevői adatokat (IPD) megosztják.

• A Study of Pembrolizumab (MK-3475) in Pediatric Participants With an Advanced Solid Tumor or Lymphoma (MK-3475-051/KEYNOTE-051)

  NCT02332668· Merck Sharp & Dohme LLC· Forrás

• Phase II Trial of Combination Anti-PD-1 and Aldesleukin for Metastatic Melanoma and Renal Cell Carcinoma

  NCT05155033· National Cancer Institute (NCI)· Forrás

• A Clinical Study of Intismeran Autogene (V940) and Pembrolizumab (MK-3475) in People With Melanoma (V940-012/INTerpath-012)

  NCT06961006· Merck Sharp & Dohme LLC· Forrás

• A Trial to See if the Combination of Fianlimab With Cemiplimab Works Better Than Pembrolizumab for Preventing or Delaying Melanoma From Coming Back After it Has Been Removed With Surgery

  NCT05608291· Regeneron Pharmaceuticals· Forrás

• A Study of Therapeutic Drug Monitoring-Based Atezolizumab Dosing

  NCT06066138· National Cancer Institute (NCI)· Forrás

• A Study With Combinations of Anti-LAG-3 and Anti-PD-1 Antibodies in Adult Participants With Advanced or Metastatic Melanoma (Harmony Head-to-Head)

  NCT06246916· Regeneron Pharmaceuticals· Forrás

• Hepzato Kit and Opdualag for Metastatic Melanoma and Liver Metastasis

  NCT07281924· University of Wisconsin, Madison· Forrás

• The Effect of Diet and Exercise on ImmuNotherapy and the Microbiome (EDEN)

  NCT04866810· National Cancer Institute (NCI)· Forrás

• Different Doses of BI-1607 in Combination With Pembrolizumab and Ipilimumab, in Participants With Unresectable or Metastatic Melanoma

  NCT06784648· BioInvent International AB· Forrás

• A Study to Evaluate the Safety and Activity of Belvarafenib as a Single Agent and in Combination With Either Cobimetinib or Cobimetinib Plus Nivolumab in Patients With NRAS-mutant Advanced Melanoma.

  NCT04835805· Genentech, Inc.· Forrás

Publikációk erről a betegségről egy MeSH-módszerkifejezés szerint, például szekvenálási vagy képalkotó módszerre.

• Single-Cell Analysis 51
• Organoids 8
• Mendelian Randomization Analysis 12
• CRISPR-Cas Systems 22
• Gene Expression Profiling 116
• Sequence Analysis, RNA 9
• Whole Genome Sequencing 6
• Exome Sequencing 7
• Proteomics 47
• Metabolomics 20
• Mass Spectrometry 10
• Flow Cytometry 65
• Immunohistochemistry 107
• Liquid Biopsy 12
• Circulating Tumor DNA 37
• Xenograft Model Antitumor Assays 121
• Positron-Emission Tomography 31
• Magnetic Resonance Imaging 57
• Machine Learning 49
• Deep Learning 44
• Cohort Studies 78
• Genome-Wide Association Study 22

• A rare ATM variant in a Colombian family with chorea-ataxia syndrome: implications for an early diagnosis.

  Neurogenetics, 2026. szept.

• Melanoma to rhabdomyosarcoma plasticity in the setting of immunotherapy.

  Med, 2026. aug.

• Genomic and Transcriptomic Analysis of Sinonasal Mucosal Melanoma and Conjunctival Melanoma.

  Int J Cancer, 2026. aug.

• Exploratory Analysis of Biomarkers and Treatment Outcomes from the COLUMBUS Study in BRAF V600E/K-Mutant Advanced or Metastatic Melanoma.

  Clin Cancer Res, 2026. ápr.

• Genetic architecture of multiple primary cutaneous melanoma in the absence of high-penetrance susceptibility genes.

  J Invest Dermatol, 2026. febr.

• Xeroderma pigmentosum with multiple skin carcinoma and a homogenous XPC mutation: A case report from China and literature review.

  J Int Med Res, 2026. jan.

• Evaluation of clonality in lentigo maligna.

  J Invest Dermatol, 2025. dec.

Megmutatjuk, a betegség mely célpontjait említi az absztrakt, és onnan a rajtuk dolgozókhoz jutsz.